Hot Features
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to pr... Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson’s disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer’s disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -1.6 | 1.25 | 1.305 | 1.202 | 75325 | 1.24727988 | CS |
| 4 | -0.05 | -3.90625 | 1.28 | 1.34 | 1.18 | 88725 | 1.26050783 | CS |
| 12 | -0.08 | -6.10687022901 | 1.31 | 1.5 | 1.1 | 136921 | 1.34431006 | CS |
| 26 | -0.18 | -12.7659574468 | 1.41 | 1.5 | 1.05 | 144826 | 1.3325147 | CS |
| 52 | -0.89 | -41.9811320755 | 2.12 | 3.1 | 1.05 | 1629357 | 1.78559376 | CS |
| 156 | -5.77 | -82.4285714286 | 7 | 20.72 | 1.05 | 770784 | 2.06057258 | CS |
| 260 | -5.77 | -82.4285714286 | 7 | 20.72 | 1.05 | 770784 | 2.06057258 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.